 pilot study low-dose zidovudine human immunodeficiency virus infection BACKGROUND Zidovudine progression human immunodeficiency virus HIV infection hematologic toxicity high doses Regimens preserve enhance efficacy toxicity Acyclovir effect zidovudine HIV vitro METHODS Phase II open-label dose-escalating trial clinical antiviral effects zidovudine low mg subjects medium mg subjects high mg subjects acyclovir random assignment subjects immunodeficiency syndrome AIDS complex AIDS HIV antigenemia plasma viremia counts cubic millimeter treatment RESULTS Performance scores fatigue low- medium-dose zidovudine groups equal low-dose zidovudine weight improvement mean count cubic millimeter base line cubic millimeter weeks proportion subjects HIV antigenemia decrease level antigenemia reduction plasma virus titers similar doses Subjects low medium dose dose increase counts decline levels HIV antigen dose-related toxicity addition acyclovir zidovudine zidovudine antiretroviral effects CONCLUSIONS pilot low dose zidovudine mg clinical virologic effects similar daily doses mg minimal effective dose zidovudine treatment HIV infection studies low daily doses